US Edition
ViGeneron Rebrands as VeonGen Therapeutics, Earns FDA Rare Pediatric Disease Status
Summary by Women In Optometry
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
ViGeneron Rebrands as VeonGen Therapeutics, Earns FDA Rare Pediatric Disease Status
VeonGen Therapeutics, formerly known as ViGeneron, announced its rebranding to reflect its evolution into a clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high unmet medical needs. VeonGen has advanced two first-in-class gene therapy programs into clinical development, marking a significant step toward addressing diseases with no approved treatment options. These programs include VG8…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
